Tamara Minko

Professor and Chair

Department of Pharmaceutics

Publications

Selected from total 334 publications: 86 journal research articles, 16 book and textbook chapters, 48 extended abstracts/conference proceedings (none shown), 184 abstracts (none shown).

  1. M. Saad, O. B. Garbuzenko, T. Minko, Co-delivery of siRNA and an anticancer drug for treatment of multidrug resistant cancer, Nanomedicine, submitted.


    2.
  2. O. B. Garbuzenko, M. Saad, S. Betigeri, M. Zhang, A. A. Vetcher, V. A. Soldatenkov, D. C. Reimer, T. Minko, Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug, Pharm. Research, submitted.


    3.
  3. M. Saad, O. B. Garbuzenko, E. Ber, P. Chandna, J. J. Khandare, V. P. Pozharov, T. Minko, Receptor - targeted nanocarriers for tumor specific treatment and imaging, J. Control. Release, 2008 Jun 24. [Epub ahead of print].


    4.
  4. M. L. Patil, M. Zhang, S. Betigeri, O. Taratula, H. He, T. Minko, Surface Modified and Internally Cationic Polyamidoamine Dendrimers for Efficient siRNA Delivery, Bioconjugate Chem., 19, 1396-403 (2008).


    5.
  5. Y. Wang, M. Saad, R. I. Pakunlu, J. J. Khandare, O. B. Garbuzenko, A. A. Vetcher, V. A. Soldatenkov, V. P. Pozharov, T. Minko, Non-viral nanoscale-based delivery of antisense oligonucleotides targeted to HIF1 alpha enhances the efficacy of chemotherapy in drug resistant tumor, Clin. Cancer Res., 14, 3607-3616 (2008).


    6.
  6. T. Minko, J. J. Khandare, A. A. Vetcher, V. A. Soldatenkov, O. B. Garbuzenko, M. Saad, V. P. Pozharov, Multifunctional nanotherapeutics for cancer (Chapter 10), In.: Multifunctional Pharmaceutical Nanocarriers, V. P. Torchilin, Ed., Springer, 2008, pp. 309-335.


    7.
  7. Y. Geng, P. Dalhaimer, S. Cai, R. Tsai, M. Tewari, T. Minko, D. E. Discher, Shape effects of filaments versus spherical particles in flow and drug delivery, Nature Nanotech., 2, 249 – 255 (2007).


    8.
  8. P. Chandna, M. Saad, E. Ber, J. J. Khandare, A. A. Vetcher, V. A. Soldatenkov, T. Minko, LHRH receptor targeting of polymer therapeutics to tumor, Mol. Pharm., 4,668-678 (2007).


    9.
  9. S. Jayant, J. J. Khandare, Y. Wang, A. P. Singh, N. Vorsa, T. Minko, Targeted Sialic Acid - Doxorubicin Prodrugs for Intracellular Delivery and Cancer Treatment, Pharm. Res., 24, 2120-2130 (2007).


    10.
  10. S. Zalipsky, M. Saad, R. Kiwan, E. Ber, N. Yu, T. Minko, Antitumor activity of new liposomal prodrug of Mitomycin C in multidrug resistant solid tumor: Insights of the mechanism of action, J. Drug Target., 15, 518-530 (2007).


  11. T. Minko, Intracellular delivery, Pharm. Res., 24, 2097-2098 (2007).


    12.
  12. T. Minko, J. J. Khandare, S. Jayant, Polymeric Drugs (Chapter 14), In.: Macromolecular Engineering: From Precise Macromolecular Synthesis to Macroscopic Material Properties and Application, Volume 4, K. Matyjaszewski, Y. Gnanou, L. Leibler, Eds., WILEY-VCH Verlag GmbH & Co., 2007, pp. 2541-2595.


  13. J. J. Khandare, T. Minko, Antibodies and peptides in cancer therapy, Crit. Rev. Ther. Drug Carrier Syst., 23, 401-435 (2006).


    14.
  14. J. J. Khandare, S. Jayant, A. Singh, P. Chandna, Y. Wang, N. Vorsa, T. Minko, Dendrimer versus linear conjugate: influence of polymeric architecture on the delivery and anticancer effect of paclitaxel, Bioconjugate Chem., 17, 1464-1472 (2006).


  15. J. J. Khandare, P. Chandna, Y. Wang, V. P. Pozharov, T. Minko, Novel polymeric prodrug with multivalent components for cancer therapy, J. Pharmacol. Exp. Ther., 317, 929-937 (2006).


    16.
  16. J. J. Khandare, T. Minko, Polymer-drug conjugates: Progress in polymeric prodrugs, Prog. Polym. Sci., 31, 359-397 (2006).


    17.
  17. S. S. Dharap, P. Chandna, Y. Wang, J. J. Khandare, B. Qiu, S. Stein, T. Minko, Molecular targeting of BCL2 and BCLXL proteins by synthetic BH3 peptide enhances the efficacy of chemotherapy, J. Pharmacol. Exp. Ther. 316, 992-998 (2006).


    18.
  18. T. Minko, R. I. Pakunlu, Y. Wang, J. J. Khandare, M. Saad, New generation of liposomal drugs for cancer, Anticancer Agents Med. Chem., 6, 537-552 (2006).


    19.
  19. R. I Pakunlu, Y. Wang, M. Saad, J. J. Khandare, V. Starovoytov, T. Minko, In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug, J. Controlled Rel., 114, 153-162 (2006).


    20.
  20. S. Betigeri, R.I. Pakunlu, Y. Wang, J.J. Khandare, T. Minko, JNK1 as a molecular target to limit cellular mortality under hypoxia, Mol. Pharm., 3, 424-430 (2006).


    21.
  21. F. Ahmed, R. I. Pakunlu, A. Brannan, F. Bates, T. Minko, D. E. Discher, Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors by inducing apoptosis in proportion to accumulated drug, J. Controlled Rel., 116, 150-158 (2006).


    22.
  22. F. Ahmed, R. I. Pakunlu, G. Srinivas, A. Brannan, F. Bates, M. L. Klein, T. Minko, D. E. Discher, Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation, Mol. Pharm, 3, 340-350 (2006).


    23.
  23. T. Minko, Hypoxia-induced lung damage and alpha tocopherol, In.: The Encyclopedia of Vitamin E, V. R. Preedy and R. Watson, Eds, CAB International, 2006, pp. 699-708.


    24.
  24. T. Minko, Chapter 22, Drug delivery systems, In: Martin’s Physical Pharmacy and Pharmaceutical Sciences 5th Edition, P. J. Sinko, Ed., Lippincott Williams and Wilkins, 2006, pp. 629-680.


    25.
  25. T. Minko, Chapter 17, Colloids, In: Martin’s Physical Pharmacy and Pharmaceutical Sciences 5th Editionn, P. J. Sinko, Ed., Lippincott Williams and Wilkins, 2006, pp. 469-498.


    26.
  26. T. Minko, Chapter 16, Interfacial Phenomena, In: Martin’s Physical Pharmacy and Pharmaceutical Sciences 5th Editionn, P. J. Sinko, Ed., Lippincott Williams and Wilkins, 2006, pp. 437-467.


    27.
  27. S. S. Dharap, Y. Wang, P. Chandna, J. J. Khandare, B. Qiu, S. Gunaseelan, P. J. Sinko, S. Stein, A. V. Farmanfarmanian, T. Minko, Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide, Proc. Natl. Acad. Sci. USA, 102, 12962-12967 (2005).


    28.
  28. D. Yu, P. Peng, S. S. Dharap, Y. Wang, M. Mehlig, P. Chandna, H. Zhao, D. Filpula, K. Yang, V. Borowski, G. Borchard, Z. Zhang, T. Minko, Antitumor activity of poly(ethylene glycol) – camptothecin conjugate: the inhibition of tumor growth in vivo, J. Controlled Rel., 110, 90-102 (2005).


    29.
  29. T. Minko, Soluble polymer conjugates for drug delivery, Drug Discovery Today, 2, 15-20 (2005).


    30.
  30. T. Minko, Y. Wang, V. Pozharov, Remediation of cellular hypoxic damage by pharmacological agents, Curr. Pharm. Des., 11, 3185-3199 (2005).


    31.
  31. T. Minko, E. V. Batrakova, S. Li, Y. Li, R. I. Pakunlu, V. Yu. Alakhov, A. V. Kabanov, Pluronic Block Copolymer Formulation with Doxorubicin Induces Apoptosis in Drug-Resistant Cancer Cells, J. Controlled Rel., 105, 269-278 (2005).


    32.
  32. T. Minko. Mechanisms of cellular drug resistance and strategies to overcome it, In: Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids, R. I. Mahato, Ed, CRC Press, Boca Raton, London, New York, Washington, D.C., 2005, pp. 461-492.


  33. Y. Wang, T. Minko, A novel cancer therapy: Liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides in combination with hypoxia and doxorubicin, Biochem. Pharmacol., 68, 2031-2042 (2004).


    34.
  34. R. I. Pakunlu, Y. Wang, W. Tsao, V. Pozharov, T. J. Cook, T. Minko, Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system, Cancer Research, 64, 6214-6224 (2004).


    35.
  35. T. Minko, S. S. Dharap, R. I. Pakunlu, Y. Wang, Molecular targeting of drug delivery systems to cancer, Curr. Drug Targets, 5, 389-406 (2004).


    36.
  36. Y. Wang, R. I. Pakunlu, W. Tsao, V. Pozharov, T. Minko, Bimodal effect of hypoxia in cancer: the role of hypoxia inducible factor in apoptosis, Mol. Pharm., 1, 156-165 (2004).


    37.
  37. T. Minko, Drug targeting to the colon with lectins and neoglycoconjugates, Adv. Drug Deliver. Rev., 56, 491-509 (2004).


    38.
  38. A. David, P. Kopeckova, T. Minko, A, Rubinstein, J. Kopecek, The involvement of endogenous lectins in mediating the antitumor activity of targetable HPMA copolymer-doxorubicin conjugates in human colon adenocarcinoma and hepatocarcinoma cells, Eur. J. Cancer, 40, 148-157 (2004).


    39.
  39. S. S. Dharap, B. Qiu, G. Williams, P. J. Sinko, S. Stein, T. Minko, Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides, J. Controlled Rel., 91, 61-73 (2003).


    40.
  40. T. Minko, S. S. Dharap, A. T. Fabbricatore, Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense, Cancer Detect. Prev., 27, 193-202 (2003).


    41.
  41. S. S. Dharap, T. Minko, Targeted proapoptotic LHRH-BH3 peptide, Pharm. Res., 20, 889-896 (2003).


    42.
  42. R. I. Pakunlu, T. J. Cook, T. Minko, Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin, Pharm. Res., 20, 351-359 (2003).


    43.
  43. T. Minko, A. Stefanov, V. Pozharov, Lung hypoxia: Antioxidant and antiapoptotic effects of liposomal alpha tocopherol, J. Appl. Physiol., 93, 1550-1560 (2002).

    44.

Department of Pharmaceutics, Ernest Mario School of Pharmacy

Rutgers, The State University of New Jersey
160-Frelinghuysen Road, Piscataway, NJ 08854-8022, USA.
Tel: (732) 445-3831*214; Fax: (732) 445-3134
For questions or suggestions on this site, please e-mail us.


Last Updated: 08/05/2008

Rutgers Home

School of Pharmacy

Department Home

Pharmaceutical Science

Minko Lab Home

 

getadobe